Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803006 · ClinicalTrials.gov registry record · Phase 2
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
A Phase 2 study, sponsored by ITB-Med.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04803006 is a Phase 2 study that was terminated before completion, run by ITB-Med. The registered enrollment target is 4 participants.
The verdict
NCT04803006, a Phase 2 study, was terminated before completion, sponsored by ITB-Med.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
Interventions
- BIOLOGICAL TCD601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04803006
The ClinicalTrials.gov registry entry for NCT04803006 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ITB-Med, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TCD601 is the first listed.
NCT04803006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04803006 about?
NCT04803006 is a clinical study titled "A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)". The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
What is the current status of trial NCT04803006?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2023-01-17. Estimated completion is 2025-10-30.
What interventions are being tested in trial NCT04803006?
The interventions under investigation include: TCD601 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04803006?
This trial is sponsored by ITB-Med, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.